Skip to content
StackItSmart
BHuman cohort / observational
High riskNeuropsychiatric

Testosterone Phenylpropionate

Test PP

Testosterone phenylpropionate ("Test PP") is an injectable ester of testosterone — the phenylpropionic-acid ester of the natural male androgen. After intramuscular injection the ester is slowly cleaved by esterases to release free testosterone, so its effects are simply those of testosterone delivered as a short-to-intermediate-acting oil depot; it has no unique pharmacology of its own. There is no dedicated standalone human pharmacokinetic or efficacy trial of testosterone phenylpropionate: in the literature it appears only as one of four esters in testosterone-blend products (e.g., Sustanon: 30 mg propionate / 60 mg phenylpropionate / 60 mg isocaproate / 100 mg decanoate) and in a small combination clinical trial for delayed puberty. Every clinical claim here is therefore anchored to testosterone-class human evidence and applied to this ester. The main risks — driven chiefly by supraphysiologic (misuse) dosing rather than clinical replacement — include adverse cardiac remodeling and accelerated coronary atherosclerosis, marked erythrocytosis (thickened blood with thrombosis risk), suppression of the body's own testosterone production and fertility (recovery can take months to years or be incomplete), lowered HDL cholesterol, mood/aggression disturbance and dependence, acne, and estrogen-related effects such as gynecomastia. Educational information only — not medical advice, and no doctor–patient relationship is created. These substances carry serious risks; anyone using or considering them should be under a physician's care with regular bloodwork. 21+ only.

Clinical readoutAAS · injectable-testosterone
Hepatic strainLow
CardiovascularHigh
HPTA suppressionVery high
Half-life
2.8 d
Route
Intramuscular injection…
Evidence
B
Active
Inferred to be several…
2.8 d5.5 d8.3 d11 d13.8 d
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ No dedicated human pharmacokinetic study of testosterone phenylpropionate as a standalone agent exists (evidence grade D for ester-specific values). By ester chemistry it is a short-to-intermediate ester — longer-acting than testosterone propionate but shorter than decanoate/undecanoate — with an estimated effective half-life on the order of ~1 to 4.5 days. Once cleaved, the released testosterone itself has a circulating half-life of only minutes to a few hours; the depot ester, not the hormone, governs dosing frequency.
Pharmacology

Mechanism of action

Testosterone phenylpropionate is a prodrug ester. After intramuscular depot injection the phenylpropionate ester is enzymatically hydrolyzed to release free testosterone, which acts identically to endogenous testosterone: it binds the intracellular androgen receptor to drive anabolic and androgenic gene transcription (increased muscle protein synthesis, secondary sexual characteristics). Testosterone is also a substrate for two key conversions — 5-alpha-reductase converts it to the more potent androgen dihydrotestosterone (mediating androgenic effects on skin, scalp, and prostate), and aromatase converts it to estradiol (mediating estrogenic effects such as gynecomastia and water retention). Through negative feedback on the hypothalamus and pituitary, exogenous testosterone suppresses gonadotropin-releasing hormone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby shutting down endogenous testicular testosterone production and spermatogenesis. It also stimulates erythropoiesis, raising hemoglobin and hematocrit. Because it is not 17-alpha-alkylated, this injectable ester lacks the intrinsic hepatotoxic mechanism of oral 17-alpha-alkylated anabolic steroids.
Kinetics

Pharmacokinetics

Half-life

No dedicated human pharmacokinetic study of testosterone phenylpropionate as a standalone agent exists (evidence grade D for ester-specific values). By ester chemistry it is a short-to-intermediate ester — longer-acting than testosterone propionate but shorter than decanoate/undecanoate — with an estimated effective half-life on the order of ~1 to 4.5 days. Once cleaved, the released testosterone itself has a circulating half-life of only minutes to a few hours; the depot ester, not the hormone, governs dosing frequency.

Active duration

Inferred to be several days per injection (no direct human data). In the blend products where this ester actually appears, dosing intervals of roughly 1 to 3 weeks are used because longer co-formulated esters extend the release; the phenylpropionate fraction is the early/intermediate-release component.

Route

Intramuscular injection of an oil-based depot. (No non-injectable formulation.)

Metabolism & clearance

The ester is hydrolyzed by plasma and tissue esterases to free testosterone. Testosterone is metabolized principally in the liver to androstenedione and, via 5-alpha-reductase, to dihydrotestosterone, and via aromatase to estradiol; it is ultimately excreted in urine largely as glucuronide and sulfate conjugates. After intramuscular injection of a four-ester testosterone blend containing this ester, urinary steroid-profile changes remain detectable for up to ~60 days — relevant for washout/monitoring reasoning and clinician discussion, not for evading testing.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Increases circulating testosterone, producing the physiological effects of testosterone once the ester is cleaved
  • Increases skeletal muscle mass and strength when dosed above physiologic replacement (an androgen-receptor-mediated anabolic effect common to testosterone)
  • Restores/raises libido, energy and secondary sexual characteristics in hypogonadal states (class effect of testosterone replacement)
  • Stimulates erythropoiesis, raising hemoglobin and hematocrit
  • Suppresses the hypothalamic-pituitary-gonadal axis, lowering LH and FSH and reducing endogenous testosterone and sperm production
  • Converts partly to estradiol (aromatization), which can cause gynecomastia and fluid retention, and to dihydrotestosterone, driving androgenic skin/scalp/prostate effects
  • No unique effect distinct from testosterone itself — the ester only changes release kinetics
Safety

Adverse effects by system

Cardiovascular

At clinical replacement doses, testosterone therapy was non-inferior to placebo for major adverse cardiac events but showed higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism (TRAVERSE RCT). At the supraphysiologic doses typical of misuse, long-term anabolic-androgenic steroid (AAS) use is associated with reduced left-ventricular systolic and diastolic function and accelerated, dose-related coronary atherosclerosis; case reports describe AAS-associated cardiomyopathy with severe LV dysfunction. Blood pressure, lipids and hematocrit rise all contribute to cardiovascular risk.

Hepatic

Injectable testosterone esters are not 17-alpha-alkylated and lack the direct hepatotoxicity characteristic of oral 17-alpha-alkylated anabolic steroids; hepatocellular adenomas/tumors in AAS users are chiefly reported with oral 17-alpha-alkylated agents rather than injectable testosterone esters. Clinically meaningful hepatotoxicity from injectable testosterone esters is uncommon.

Endocrine / HPTA

Predictable, dose-dependent suppression of the hypothalamic-pituitary-gonadal axis: exogenous testosterone lowers LH and FSH and suppresses or halts endogenous testosterone production and spermatogenesis. Recovery after discontinuation is variable and may take months to years, and is not guaranteed to be complete.

Reproductive

Testicular atrophy, reduced or absent sperm production (impaired fertility/infertility), and reduced ejaculate volume from HPGA suppression. Aromatization to estradiol can cause gynecomastia. Fertility usually declines during use; recovery post-cessation is variable and sometimes incomplete.

Neuropsychiatric

Higher-dose AAS use is associated with affective (mood) and, less commonly, psychotic syndromes, irritability/aggression, and psychological dependence; most users do not develop severe disturbance, but a subset does. Mood changes and hypomania/depression (the latter notably on withdrawal) are described.

Renal

No strong evidence of direct nephrotoxicity from testosterone at replacement doses; however the TRAVERSE trial recorded a higher incidence of acute kidney injury in the testosterone group. Secondary renal strain can occur via elevated blood pressure and, in misuse settings, via rhabdomyolysis or nephropathy reported with broader AAS abuse. Compound-specific renal data are lacking.

Hematologic

Stimulation of erythropoiesis raises hemoglobin and hematocrit (a meta-analysis of testosterone trials found significant increases). Erythrocytosis/polycythemia thickens the blood and raises thrombotic risk (stroke, venous thromboembolism), a recognized drug-induced cause of secondary erythrocytosis.

Dermatologic

Androgenic skin effects are common: acne (often on the back/shoulders), oily skin, and accelerated male-pattern scalp hair loss in genetically predisposed individuals, mediated by conversion to dihydrotestosterone. Injection-site reactions are also possible.

Recovery

HPTA suppression & recovery

Suppression: Marked (high) and dose-dependent

Exogenous testosterone reliably suppresses LH and FSH and shuts down endogenous testosterone and sperm production. After stopping, recovery of the axis is highly variable — it may take many months to years and can be incomplete, and no study reliably predicts the timeline or whether sperm counts will return to a fertile range for a given individual. Any recovery strategy should be directed by an endocrinologist or fertility specialist; where pharmacologic support is described in the literature, a single selective-estrogen-receptor-modulator (SERM) approach is one option, but management (including monitoring and decisions about additional agents) must be individualized and clinician-supervised. Dual-SERM protocols are out of scope here. Do not self-manage recovery.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Hematocrit and hemoglobin (screen for erythrocytosis)Total testosterone (and where indicated free testosterone)LH and FSH (axis suppression)EstradiolLipid panel (HDL, LDL, triglycerides)Liver function tests (AST, ALT, bilirubin)Renal function (creatinine, eGFR)Prostate-specific antigen (PSA) and prostate exam in appropriate-age menBlood pressureSemen analysis if fertility is a concern

Cadence: Establish a baseline before any use, recheck at roughly 3 and 6 months after starting or changing dose, then at least every 6–12 months while continuing, under a clinician's direction. Hematocrit and blood pressure warrant closer surveillance if trending up.

Warning signs — seek care
  • Chest pain, shortness of breath, leg swelling or pain (possible thrombosis/pulmonary embolism/cardiac event) — seek emergency care
  • Symptoms of high hematocrit: headaches, flushing, visual changes, dizziness
  • New or worsening high blood pressure
  • Palpitations or irregular heartbeat (atrial fibrillation)
  • Yellowing of skin/eyes, dark urine, right-upper-abdominal pain (liver concern)
  • Severe mood changes, aggression, depression or suicidal thoughts
  • Breast tenderness or enlargement (gynecomastia)
  • Testicular shrinkage, loss of libido, or infertility
  • Decreased urine output or swelling (kidney concern)
Do not use if

Contraindications

  • Known or suspected prostate cancer or breast cancer in men
  • Pregnancy and breastfeeding (androgens can virilize a female fetus/infant); women generally, due to virilization
  • Untreated/uncontrolled polycythemia or baseline elevated hematocrit
  • Untreated severe obstructive sleep apnea
  • Uncontrolled or severe heart failure and recent cardiovascular events (higher-risk setting)
  • Desire to preserve near-term fertility (suppresses spermatogenesis)
  • Uncontrolled hypertension
  • Known hypersensitivity to the formulation or its oil vehicle/excipients
  • Severe hepatic or renal impairment (relative caution; requires specialist oversight)
Combinations

Interaction profile

  • MajorWith another anabolic steroid: Additive cardiovascular strain
  • MajorWith a thermogenic stimulant: Additive cardiovascular strain
  • ModerateWith thyroid hormone: Additive cardiovascular strain
  • ModerateWith growth hormone: Additive cardiovascular strain
  • MajorWith another anabolic steroid: Blood / clotting
  • MajorWith a clot-promoting SERM: Blood / clotting
  • ModerateWith an aromatase inhibitor: Hormonal
  • ModerateWith an anabolic steroid: Hormonal
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Educational information only — not medical advice. The safest course is medical supervision with regular bloodwork, not self-directed use.
  • Get baseline labs before any use and recheck periodically (hematocrit, lipids, testosterone, LH/FSH, estradiol, PSA, liver and kidney function, blood pressure).
  • Rising hematocrit is a common, serious effect; a persistently elevated or climbing hematocrit should prompt medical review because of stroke/clot risk — do not ignore it.
  • Stop and seek emergency care for chest pain, breathlessness, one-sided leg swelling, sudden severe headache, vision changes, or signs of stroke — these can signal a clot or cardiac event.
  • Suppression of your own testosterone and fertility is expected; if fertility matters, discuss it with a specialist before use, since recovery is variable and can be incomplete.
  • Any attempt to restore the hormonal axis after stopping should be directed by an endocrinologist; do not self-manage recovery. Single-SERM approaches are described in the literature but must be clinician-supervised.
  • Watch for and report mood changes, aggression, or depression (especially on withdrawal); involve a clinician early.
  • Illicitly obtained injectables are frequently counterfeit, under- or over-dosed, or contaminated, adding infection and unpredictable-dose risks on top of the drug's own hazards.
  • Seek care promptly for jaundice, dark urine, abdominal pain, breast enlargement, or decreased urine output.
  • Do not use if pregnant, breastfeeding, or if you have or may have prostate or breast cancer.
Evidence

Citations (12)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Testosterone phenylpropionate is one of four esters in the blend product Sustanon (30 mg propionate / 60 mg phenylpropionate / 60 mg isocaproate / 100 mg decanoate), given intramuscularly, with urinary steroid-profile changes detectable up to ~60 days after injection.

    CohortQuantification of endogenous steroid sulfates and glucuronides in human urine after intramuscular administration of testosterone esters.PMID 32097612 ↗

  2. 02

    Testosterone phenylpropionate has been used clinically only as part of a combination of testosterone esters (propionate + phenylpropionate + isocaproate) administered intramuscularly, e.g., for constitutional delayed puberty — there is no standalone human trial of the phenylpropionate ester alone.

    CohortTreatment of constitutional delayed puberty with a combination of testosterone esters.PMID 8719438 ↗

  3. 03

    At clinical replacement doses in high-cardiovascular-risk hypogonadal men, testosterone therapy was non-inferior to placebo for major adverse cardiac events but was associated with higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism.

    RCTCardiovascular Safety of Testosterone-Replacement Therapy.PMID 37326322 ↗

  4. 04

    Long-term (supraphysiologic) anabolic-androgenic steroid use is associated with reduced left-ventricular systolic and diastolic function and accelerated, dose-related coronary atherosclerosis.

    CohortCardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid UsePMID 28533317 ↗

  5. 05

    Testosterone treatment significantly increases hemoglobin and hematocrit and produces a small decrease in HDL cholesterol.

    Meta-analysisClinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysisPMID 20525906 ↗

  6. 06

    Testosterone (as a drug) is a recognized cause of secondary erythrocytosis/polycythemia, which raises blood viscosity and thrombotic risk.

    ReviewJAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches.PMID 41347984 ↗

  7. 07

    Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis via negative feedback, lowering LH and FSH and partially or completely halting spermatogenesis; recovery time after discontinuation is variable and not reliably predictable.

    ReviewSuppression of Spermatogenesis by Exogenous Testosterone.PMID 33292112 ↗

  8. 08

    Anabolic-steroid-induced hypogonadism and infertility are managed by specialists; recovery of spermatogenesis is variable and may require clinician-directed pharmacologic support, and management should defer to a fertility/endocrine specialist.

    ReviewManagement of Anabolic Steroid-Induced Infertility: Novel Strategies for Fertility Maintenance and Recovery.PMID 30929329 ↗

  9. 09

    AAS-associated male infertility recovery strategies are clinician-directed and individualized; users frequently underestimate the fertility consequences of androgen use.

    ReviewAnabolic steroid misuse and male infertility: management and strategies to improve patient awareness.PMID 33973822 ↗

  10. 10

    Higher-dose anabolic-androgenic steroid use is associated with affective and psychotic syndromes and psychological dependence, though only a small percentage of users develop severe disturbance.

    ReviewPsychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update.PMID 8969015 ↗

  11. 11

    Injectable anabolic-steroid products, including testosterone phenylpropionate, are frequently counterfeited or adulterated — analysis of seized products found missing active ingredient, substitution, or under-labeled concentrations.

    Case series1H NMR determination of adulteration of anabolic steroids in seized drugs.PMID 30003910 ↗

  12. 12

    Hepatic adenomas/tumours in AAS users are chiefly associated with 17a-alkylated oral agents; cases with non-17a-alkylated injectable esters are rare and individually notable.

    Case reportPMID 2997324 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice